US EditionPublished • loading... • Updated
FDA Approves GLP-1 Pill for Cardiovascular Risk in Type 2 Diabetes
Summary by JAMA Network
1 Articles
1 Articles
FDA Approves GLP-1 Pill for Cardiovascular Risk in Type 2 Diabetes
The US Food and Drug Administration (FDA) recently approved Novo Nordisk’s oral semaglutide, marketed as Rybelsus, to reduce the risk of major adverse cardiac events in adults with type 2 diabetes who are at high risk of these conditions.
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
